Acetylsalicylic Acid

證據等級: L5

預測適應症: 9 個

A quick methodological note before the report: this evidence pack actually contains 9 predicted indications for aspirin with very different evidence quality — from essentially unsupported hits (e.g., atrophoderma vermiculata, ulerythema ophryogenesis, score >0.99 but zero literature/trials) to already well‑established uses (e.g., thrombotic disease, rank 8, L1 evidence, "Proceed with Guardrails"). Per the report specification, the primary report below covers only rank 1 (predicted_indications[0]). I flag the stronger, lower‑ranked candidates in the Conclusion since they are relevant context for decision‑making, but they are outside the formal scope of this single‑indication report format.

Acetylsalicylic Acid: From Antiplatelet/Analgesic Therapy to Migraine with Brainstem Aura

One-Sentence Summary

Acetylsalicylic acid (aspirin) is a long-established analgesic, antipyretic, anti-inflammatory, and antiplatelet drug. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, with 0 disease-specific clinical trials but 19 supporting publications — mostly general migraine-with-aura literature rather than trials on this exact subtype. Evidence is currently hypothesis-generating rather than confirmatory.

Quick Overview

Item	Content
Original Indication	No license text on file in the Fimea dataset (data gap, see DG001); aspirin is broadly established for analgesia, antipyresis, anti-inflammatory therapy, and antiplatelet/cardiovascular prophylaxis
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.94% (rank 947 among all predictions)
Evidence Level	L3
Finland Market Status	✗ Not Marketed (per current dataset)
Number of Authorizations	0
Recommended Decision	Hold (Research Question stage)

Why is This Prediction Reasonable?

Detailed, structured mechanism-of-action data for aspirin is not available in this evidence pack (data gap DG002, High severity). Based on well-established pharmacological knowledge, however, aspirin is an irreversible COX-1/COX-2 inhibitor that blocks prostaglandin (PGE2) synthesis and, at low doses, permanently inactivates platelet thromboxane A2 production — giving it combined anti-inflammatory and antiplatelet effects.

Migraine with aura is thought to be driven by cortical spreading depression, trigeminovascular activation, neurogenic inflammation, and platelet/serotonin (5-HT) release during attacks. Aspirin's anti-inflammatory action (PGE2 synthesis inhibition) and antiplatelet effect could plausibly reduce neurogenic inflammation and platelet-mediated 5-HT release during an attack. The link is arguably strongest for the brainstem aura subtype specifically: this subtype is traditionally considered a relative contraindication for vasoconstrictive agents such as triptans (due to brainstem/basilar territory involvement), whereas aspirin has no vasoconstrictive action. This gives aspirin a theoretical mechanistic advantage as a non-vasoconstrictive option in exactly the population where the first-line acute drug class is discouraged.

That said, this mechanistic argument is currently an extrapolation. Almost all of the supporting literature addresses "migraine with aura" in general — not migraine with brainstem aura specifically — so the disease-specificity of the evidence is weak even though the general drug-class rationale is sound.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10448545	1999	RCT (double-blind, double-dummy)	Cephalalgia	IV lysine acetylsalicylate vs. subcutaneous sumatriptan vs. placebo in 278 acute migraine patients (with/without aura); ASA showed efficacy broadly comparable to sumatriptan
39989443	2025	Systematic Review	Headache	Reviews evidence on antithrombotic drugs (including aspirin) as migraine preventive therapy
25729594	2014	Retrospective Cohort	Current Health Sciences Journal	203 migraine-with-aura patients; ASA (low dose, n=95) compared with other prophylactic therapies (n=108) for efficacy/tolerability in aura prevention
29017164	2017	Observational Case Series	European Neurology	Aspirin used as prophylaxis specifically for migraine with aura
25600718	2015	Guideline / Evidence Assessment (AHS)	Headache	American Headache Society evidence assessment of acute migraine pharmacotherapies, including aspirin-containing regimens
30291554	2018	Review	Current Pain and Headache Reports	Compares pathophysiology and management of episodic migraine with vs. without aura
34384631	2021	Review	Revue Neurologique	Overview of migraine-with-aura pathophysiology, centered on cortical spreading depression
26908949	2016	RCT (PRIMA trial)	European Heart Journal	Randomized trial of percutaneous PFO closure in migraine with aura — relevant to the aura/vascular mechanism link, not aspirin itself
10534294	1999	Review	Journal of Women's Health & Gender-Based Medicine	Reviews menstrual migraine, largely without aura; hormonal influence on migraine frequency
15891416	2005	Review	Current Opinion in Neurology	Discusses the PFO–migraine–stroke relationship relevant to aura pathophysiology

9 additional lower-relevance publications (general headache/triptan reviews, case reports) were identified but are not shown here; none specifically address migraine with brainstem aura or test aspirin in that subtype.

Finland Market Information

No marketing authorizations are on file for acetylsalicylic acid in the current dataset (0 licenses; status: Not Marketed). This is likely a data-source limitation rather than a true absence from the Finnish market — aspirin is a globally available, long-genericized OTC drug, and this gap should be verified against Fimea's product register directly before being treated as a factual finding.

Safety Considerations

Please refer to the package insert for safety information.

(No structured warnings, contraindications, or DDI data were retrievable for this candidate — see data gap DG001, Blocking severity, which also prevents a formal S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence level is L3 (observational cohort + case series + reviews), with zero clinical trials specific to migraine with brainstem aura — the supporting literature almost entirely addresses migraine with aura in general, not this specific subtype.
Two blocking/high-severity data gaps (Fimea package insert/warnings — DG001; DrugBank MOA — DG002) prevent even a preliminary safety screen (S1), so no safety-based comparison against triptan contraindications in this subtype can be made yet.

To proceed, the following is needed:

Resolve DG001: obtain Fimea package insert (warnings, contraindications) to enable a formal S1 safety pre-assessment
Resolve DG002: structured DrugBank MOA extraction to firm up the mechanistic rationale
A prospective study or registry analysis specifically in migraine-with-brainstem-aura patients (current evidence is aura-general, not subtype-specific)
Clarification of Finland market/licensing status, since "0 licenses" for a globally marketed OTC drug looks like a data gap rather than fact

Additional context for portfolio prioritization: this evidence pack's other TxGNN candidates for aspirin include several with much stronger evidence at lower TxGNN rank — notably thrombotic disease (rank 8, evidence level L1, "Proceed with Guardrails") and thrombophilia (rank 9, L2, "Proceed with Guardrails"). These reflect aspirin's already well-established antithrombotic role rather than a novel repurposing opportunity, but may be more actionable near-term than the brainstem-aura candidate covered in this report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.